ARMGO,Pharma,Inc. Company
ARMGO Pharma, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. It offers rycals, which are calcium release channel stabilizers that act on ryanodine receptor/calcium release channel, a therapeutic target located on the sarcoplasmic/endoplasmic reticulum of the cell for treating chronic heart failure, cardiac arrythmias, and muscle disorders, as well as cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. The company was incorporated in 2004 and is based in Tarrytown, New York with an additional office in New York, New York.
Industry:
Geroscience
Headquarters:
Tarrytown, New York, United States
Zip:
11-50
Founded Date:
2004-01-01
Employees Number:
11-50
Acquisitions Number:
3
Investors Number:
36000000
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Series B
Last Funding Type:
info@armgo.com
Register and Claim Ownership